Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial (Businesswire) - Apr 5, 2023 - P3 | N=358 | AURORA (NCT03021499) | Sponsor: Aurinia Pharmaceuticals Inc. | "Aurinia Pharmaceuticals Inc...announced promising results from the AURORA Renal Biopsy Sub-Study....The patients in the voclosporin treatment arm demonstrated histologic activity improvement with stable chronicity scores similar to the active control arm of MMF and low dose steroids alone over the 18-months average treatment period at the time of repeat biopsy....Compared to baseline, the activity scores for both LUPKYNIS and active control populations improved to a similar degree, while the chronicity scores remained stable over time in both arms....Further data will be presented at the upcoming Congress of Clinical Rheumatology meeting, May 4-7, 2023. Aurinia will host a conference call/webcast at 8:30 am EDT to review these results."
P3 data: top line • Immunology • Lupus Nephritis
|